Detralex, 1000 mg 60 pcs

Detralex® has venotonic and angioprotective properties. The drug reduces venous distensibility and venous stasis, reduces capillary permeability and increases their resistance.

The results of clinical studies confirm the pharmacological activity of the drug with respect to the parameters of venous hemodynamics. Statistically significant dose-dependent effect of the drug Detralex® has been shown for the following venous plethysmographic parameters:

• venous capacity,
• venous distensibility,
• time of venous emptying.

The optimal ″dose-effect ratio″ is observed when taking 1000 mg daily. Detralex® increases venous tone: venous occlusion plethysmography has been shown to decrease venous emptying time.

In patients with signs of severe microcirculatory disorders after therapy with Detralex® a statistically significant increase of capillary resistance evaluated by angiostereometry was noted compared to placebo.

Therapeutic effectiveness of the drug Detralex® has been proven in the treatment of chronic diseases of the lower limbs veins and in the treatment of hemorrhoids.

Indications

Detralex® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Treatment of symptoms of venous-lymphatic insufficiency:
– pain;
– spasms of the lower extremities;
– feeling of heaviness and fullness in the legs;
– “fatigue” of the legs.

Treatment of manifestations of venous-lymphatic insufficiency:
– swelling of the lower extremities;
– trophic changes in the skin and subcutaneous tissue;
– venous trophic ulcers.

Symptomatic treatment of acute and chronic hemorrhoids.

Pharmacological effect

Pharmacotherapeutic group
Venotonic and venoprotective agent.
ATX code: C05CA53
Pharmacological properties
Pharmacodynamics
Detralex® has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics.
A statistically significant dose-dependent effect of the drug Detralex® was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. Optimal
the dose-effect relationship is observed when taking 1000 mg per day.
Detralex® increases venous tone: using venous occlusion plethysmography, a decrease in the time of venous emptying was shown. In patients with signs of severe microcirculation disorders, after therapy with Detralex®
There is a (statistically significant, compared to placebo) increase in capillary resistance, assessed by angiostereometry.
The therapeutic effectiveness of the drug Detralex® has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
Pharmacokinetics
The main excretion of the drug occurs in the feces. On average, about 14% of the administered amount of the drug is excreted in the urine.
The half-life is 11 hours.
The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Special instructions

– Before you start taking Detralex®, it is recommended to consult your doctor.
– When treating hemorrhoids, the use of Detralex® does not replace the specific treatment of other diseases of the rectum and anal canal. When using the drug on your own, do not exceed the maximum duration and recommended doses,
indicated in the section “Method of administration and dosage”. If symptoms of hemorrhoids persist after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy.
– In the presence of venous circulation disorders, the maximum effect of treatment is ensured by a combination of therapy with additional therapeutic and preventive measures / a healthy (balanced) lifestyle: it is advisable to avoid
long exposure to the sun, long periods of standing, and reduction of excess body weight is also recommended. Walking and, in some cases, wearing special stockings helps improve blood circulation.
Consult your doctor immediately if, during treatment, your condition worsens or your symptoms do not improve.

Impact on the ability to drive vehicles and machinery
Clinical studies have not been conducted to study the effect of the drug Detralex® on the ability to drive a car and perform work that requires a high speed of mental and physical reactions. However, based on the available safety data, we can conclude that Detralex® does not affect (has no significant effect) on these processes.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

One film-coated tablet contains:
Active ingredient: 1000 mg of purified micronized flavonoid fraction, consisting of diosmin 900 mg (90%) and flavonoids, calculated as hesperidin 100 mg (10%).
Excipients: purified water, gelatin, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch type A, talc.
Film shell: sodium lauryl sulfate, macrogol 6000, premix for the film shell of orange-pink color, consisting of: glycerol, magnesium stearate, hypromellose, macrogol 6000, magnesium stearate, red iron oxide dye, titanium dioxide, yellow iron oxide dye

Pregnancy

Pregnancy
There are no or limited data on the use of purified micronized flavonoid fraction in pregnant women.
Animal studies have not shown reproductive toxicity.
As a precautionary measure, it is preferable not to use Detralex® during pregnancy.
Breastfeeding period
It is unknown whether the purified micronized flavonoid fraction (metabolites) passes into human breast milk.
A risk for newborns and infants cannot be excluded. It is necessary to make a decision either to stop breastfeeding or to cancel therapy with Detralex®, taking into account the benefits of breastfeeding for the child and the benefits of therapy for the woman.
Effect on reproductive function
Reproductive toxicity studies showed no effect on reproductive function in rats of either sex.

Contraindications

Hypersensitivity to the active components or excipients included in the drug.
Pregnancy and breastfeeding (limited or no experience with use).
Children under 18 years of age (no experience of use).

Side Effects

Side effects of Detralex® observed during clinical studies were mild in severity. Disorders from the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting) were predominantly observed.
While taking the drug Detralex®, the following side effects were reported in the following gradation: very often (>1/10); often (>1/100, 1/1,000, 1/10,000, <1/1,000); extremely rare (< 1/10,000), unspecified frequency (frequency cannot be calculated from available data).
Nervous system disorders:
Rarely: dizziness, headache, general malaise.
Gastrointestinal disorders:
Common: diarrhea, dyspepsia, nausea, vomiting.
Uncommon: colitis.
Unspecified frequency: abdominal pain.
Disorders of the skin and subcutaneous tissues:
Rarely: skin rash, itching, urticaria.
Unspecified frequency: isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema.

Inform your doctor if you experience any unwanted reactions or sensations, including those not mentioned in these instructions, as well as changes in laboratory parameters during therapy.

Interaction

Clinical studies have not been conducted to study the interaction of the drug Detralex® with other drugs. To date, no cases of drug interactions have been reported.

Overdose

Symptoms
Data on cases of overdose of Detralex® are limited. The most common adverse reactions in cases of overdose were gastrointestinal disorders (diarrhea, nausea, abdominal pain) and skin reactions (itching, rash).
Treatment
Help in case of overdose should consist of eliminating clinical symptoms.
In case of overdose of the drug, you should immediately consult a doctor.

Storage conditions

Store at a temperature not exceeding 30 °C.
Keep out of the reach of children.

Shelf life

4 years.
Do not use after the expiration date stated on the package.

Manufacturer

Servier Rus LLC, Russia